Clinical trial NCT05147662: A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood
Official title: A Phase 3, Single Group Treatment, Open-label, Study to Evaluate the Safety of BAY 94-9027 Infusions for Prophylaxis and Treatment of Bleeding in Previously Treated Children Aged 7 to <12 Years With Severe Hemophilia A
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Treatment of Bleeding
Prophylaxis of Bleeding
Hemophilia A
Children
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2021-12-07
Enrollment: 35
Sex: MALE
Minimum age (years): 7
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Researchers are looking for a better way to treat hemophilia A. Hemophilia A is a genetic disorder where the body does not create enough of a protein called clotting factor 8 (FVIII) present in the blood. People with hemophilia A may bleed for a long time from minor wounds, have painful bleeding into joints, or have internal bleeding. In severe hemophilia A (clotting factor 8 levels less than 1%) bleedings are more likely to happen.

In this study researchers want to learn more about the treatment called BAY94-9027. BAY94-9027 is an injectable medicine used to replace missing clotting factor 8. In BAY94-9027 the clotting factor 8 has been pegylated (combined with a substance called polyethylene glycol (PEG)). This is to make the treatment last longer in the body so that less injections are required. BAY94-9027 is already available for the prevention and treatment of bleeding in adults and children who are 12 years and older. BAY 94-9027 is also called Jivi.

BAY94-9027 is not yet available for children aged 7 to less than 12 years. One potential specific risk of pegylated drugs is that proteins in the blood called antibodies are built. These may attach to the pegylation part of the drug and this in turn may lead to allergic reactions and the drug not working as well as it should during first 4 infusions. In studies that have been done so far, this has been seen in some children younger than six years, but not in 29 children aged 6 to less than 12 years treated with BAY94-9027. Further safety information related to how the body reacts to BAY94-9027 is however still needed for this age group.

The main purpose of this study is to learn how safe BAY94-9027 is (safety) and how it affects the body (tolerability) in previously treated children with severe hemophilia A who are between 7 to less than 12 years. To answer this question, the researchers will study information about two medical problems of special interest, if allergic reactions occur (also called hypersensitivity) and if the drug is not working as well as it should (also called loss of efficacy) during the first 4 infusions.

Allergic reactions may range from mild local reactions to widespread effects such as shortness of breath, skin rashes and low blood pressure. Only allergic reactions related to the study treatment will be considered.

The assessment if loss of efficacy occurred will be based on the occurrence of bleeding, the clotting factor 8 level in blood after injection called recovery, clotting factor 8 inhibitor tests and measurement of antibodies against the PEG.

The study has two parts, A and B. Part A takes 6 months and part B takes 18 months. In part A the participants will receive two injections of BAY94-9027 per week. In part B, the number of injections may be decreased, with up to five days between the injections. The participants in this study will visit the study site around 14 times and will have 15 phone visits. In part A, visit 1 is for screening. Visits 2 to 5 take place twice a week for two weeks. Visit 6 two weeks after visit 5, visits 7 to 10 take place monthly with visit 11 six weeks after visit 10. In part B, site visits will occur on month 9, 12, 18 and 24 and phone calls every month between the site visits. The participants' and their caregivers will record in an electronic patient diary information about when the study treatment was given and bleeding episodes that have happened.

During the study, the study doctors and their team will

* take blood samples,
* do physical examinations,
* review the participants' electronic diary
* ask questions about the participants' quality of life,
* ask the participants questions about how they are feeling and what adverse events they are having An adverse event is a medical problem that happens during the study. Doctors keep track of all adverse events that happen in study, even if they do not think the adverse events might be related to the study treatments.


Eligibility criteria: Inclusion Criteria:

* Participants with severe hemophilia A (participant's own FVIII activity \[FVIII:C\] \<1%)
* Participants must be previously treated with FVIII concentrate(s) (plasma derived or recombinant) for a minimum of 50 exposure days (EDs) at the time of signing the informed consent
* Participant has understood the study if appropriate for his age, informed consent must be signed by the parent, the participant can only sign the assent
* Willingness and ability of participants and/or parents /caregivers to complete training in the use of the electronic patient diary (EPD) and to document infusions during the study

Exclusion Criteria:

* History of FVIII inhibitors
* Current evidence of inhibitor to FVIII measured using the Nijmegen-modified Bethesda assay (≥0.6 BU/mL) at the time of screening (central laboratory)
* Any other inherited or acquired bleeding disorder in addition to hemophilia A (e.g. von Willebrand disease, hemophilia B)
* Known hypersensitivity or allergic reaction to drug substance, excipients or mouse or hamster protein
* Any other significant medical condition that the investigator feels would be a risk to the patient or would impede the study
* Requires any pre-medication to tolerate FVIII treatment (e.g. antihistamines)
* Planned major surgery during the study
* Any individual who is receiving chemotherapy, immune modulatory drugs other than anti-retroviral chemotherapy, or chronic use of oral or intravenous (IV) corticosteroids (\> 14 days) within the last 3 months
* Any individual who received commercially available subcutaneous factor substitution therapy (emicizumab) within the last 6 months
* The participant is currently participating in another investigational drug study or has participated in a clinical study involving an investigational drug within 30 days of study entry or previous participation in a clinical study with BAY94-9027

Primary outcomes:
measure: AESI (hypersensitivity and loss of efficacy) associated with the first 4 exposure days leading to discontinuation
timeFrame: Up to 6 months
Secondary outcomes:
measure: Adverse drug reactions (ADRs)
timeFrame: Up to 6 months
measure: Anti-drug antibody (ADA) development
timeFrame: Pre-infusion and up to 6 months
measure: The number of participants with confirmed Factor VIII inhibitors
timeFrame: Pre-infusion and up to 6 months
measure: Annualized bleeding rate (ABR)
timeFrame: Up to 24 months
measure: BAY94-9027 consumption
timeFrame: Up to 24 months
measure: Number of infusions/month and year (Annualized Infusion Rate)
timeFrame: Up to 24 months
Other outcomes:
Locations:
city: Orlando
country: United States
facility: Arnold Palmer Hospital for Children
state: Florida
city: La Plata
country: Argentina
facility: Hospital de Niños Sor María Ludovica
state: Buenos Aires
city: Buenos Aires
country: Argentina
facility: Organizacion Medica de Investigacion (OMI)
state: Ciudad Auton. De Buenos Aires
city: Godoy Cruz
country: Argentina
facility: Instituo Hematología Arbesú
state: Mendoza
city: Rosario
country: Argentina
facility: Instituto de Hematología Dr. Rubén Dávoli
state: Santa Fe
city: Rio de Janeiro
country: Brazil
facility: HEMORIO
state: RJ
city: Campinas
country: Brazil
facility: Hospital das Clínicas de Campinas - UNICAMP
state: Sao Paulo
city: Ribeirão Preto
country: Brazil
facility: Hosp Clínicas Facult. Med. de Ribeirão Preto / USP
state: Sao Paulo
city: São Paulo
country: Brazil
facility: Irmandadade da Santa Casa de Misericordia de Sao Paulo (iSANTACASA)
state: Sao Paulo
city: Multiple Locations
country: Brazil
facility: Many Locations
city: Calgary
country: Canada
facility: Alberta Children's Hospital - Hematology / Oncology / Blood and Marrow Transplant Clinic
state: Alberta
city: Hamilton
country: Canada
facility: McMaster Children's Hospital
state: Ontario
city: Multiple Locations
country: Canada
facility: Many Locations
city: Napoli
country: Italy
facility: AORN Santobono-Pausilipon
state: Campania
city: Roma (RM)
country: Italy
facility: Ospedale Pediatrico Bambino Gesù - Oncoematologia, Trapianto Emopoietico e Terapie Cellulari
state: Lazio
city: Oslo
country: Norway
facility: OUS Rikshospitalet Klinisk Forskningspost Barn
city: Adana
country: Turkey
facility: Acibadem Adana Hastanesi
city: Ankara
country: Turkey
facility: Hacettepe Universitesi Tip Fakultesi
city: Antalya
country: Turkey
facility: Akdeniz Universitesi Tip Fakultesi Hastanesi
city: Gaziantep
country: Turkey
facility: Gaziantep Universitesi Tip Fakultesi
city: Izmir
country: Turkey
facility: Ege Universitesi Tip Fakultesi
city: Multiple Locations
country: Turkey
facility: Many Locations
city: Samsun
country: Turkey
facility: Ondokuz Mayis Uni Tip Fakultesi
Study officials:
References: